Focus Partners Wealth Makes New Investment in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 45,818 shares of the company’s stock, valued at approximately $31,000.

Several other institutional investors also recently bought and sold shares of KPTI. Geode Capital Management LLC increased its holdings in Karyopharm Therapeutics by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after purchasing an additional 36,922 shares during the period. Marshall Wace LLP increased its holdings in shares of Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after acquiring an additional 319,187 shares during the period. TD Waterhouse Canada Inc. purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at $32,000. Silverarc Capital Management LLC increased its holdings in shares of Karyopharm Therapeutics by 6.7% in the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock valued at $403,000 after acquiring an additional 37,524 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its holdings in shares of Karyopharm Therapeutics by 46.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock valued at $4,274,000 after acquiring an additional 2,000,000 shares during the period. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on KPTI shares. Wall Street Zen downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 14th. Robert W. Baird cut their price target on Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Barclays lifted their price target on Karyopharm Therapeutics from $5.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, May 13th. Royal Bank of Canada lowered their price objective on Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright boosted their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $43.20.

Karyopharm Therapeutics Stock Performance

Shares of KPTI opened at $4.59 on Tuesday. The stock has a 50-day moving average of $5.17 and a two-hundred day moving average of $8.31. Karyopharm Therapeutics Inc. has a one year low of $3.51 and a one year high of $17.40. The stock has a market cap of $39.66 million, a P/E ratio of -4.50 and a beta of 0.33.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Monday, May 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.21) by $1.44. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $35.12 million. Analysts predict that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).